Deutenzalutamide

氘恩扎鲁胺

Report date: 2025/11/20 14:40:20
NME

Base Information

Drug NameDeutenzalutamide
Drug Alias Name氘恩扎卢胺Deuterated enzalutamide氘恩扎鲁德恩鲁胺胺德恩鲁胺氘恩杂鲁胺 +[8] 
ClassificationSmall molecules > Heterocyclic drugsSmall molecules > Deuterated drugs
Mechanisms of ActionAndrogen Receptor antagonists
TargetsAndrogen Receptor
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Prostatic Neoplasms, Castration-Resistant
Global Approved IndicationsProstatic Neoplasms, Castration-Resistant
Approved Indications in ChinaProstatic Neoplasms, Castration-Resistant
Original Approved Country/TerritoryMainland China
Original Approved Date2025/05/27
Country/TerritoryCanadaUnited StatesPoland +[15] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesHinova Pharmaceuticals Inc
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesHinova Pharmaceuticals IncSichuan Haisco Pharmaceutical Co Ltd
Inactive CompaniesHinova Pharmaceuticals (Usa) IncApplied Biology Inc
Active IndicationsProstatic Neoplasms, Castration-Resistant
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)

Other Information

ATC CodeN/A
Related LinksN/A